167215-66-9Relevant academic research and scientific papers
Radiolabeled platelet GPIIb/IIIa receptor antagonists as imaging agents for the diagnosis of thromboembolic disorders
-
, (2008/06/13)
This invention provides novel radiopharmaceuticals that are radiolabeled cyclic compounds containing carbocyclic or heterocyclic ring systems which act as antagonists of the platelet glycoprotein IIb/IIIa complex; to methods of using said radiopharmaceuticals as imaging agents for the diagnosis of arterial and venous thrombi; to novel reagents for the preparation of said radiopharmaceuticals; and to kits comprising said reagents.
Tc-99m-labeled fibrinogen receptor antagonists: Design and synthesis of cyclic RGD peptides for the detection of thrombi
Harris, Thomas D.,Rajopadhye, Milind,Damphousse, Paul R.,Glowacka, Danuta,Yu, Karmine,Bourque, Jeffrey P.,Barrett, John A.,Damphousse, David J.,Heminway, Stuart J.,Lazewatsky, Joel,Mazaika, Theresa,Carroll, Timothy R.
, p. 1741 - 1746 (2007/10/03)
Tc-99m labeled derivatives of N-Me-Arg-Gly-Asp containing cyclic peptide GP IIb/IIIa receptor antagonists are potential radiopharmaceuticals for the diagnosis of thrombosis. The design and synthesis of these peptides are described. These compounds are incorporated in rapidly growing thrombi under both arterial and venous conditions in canine models. Thrombi are clearly visible in images acquired at 50 min.
